Last reviewed · How we verify
Other systemic treatments for PsO
At a glance
| Generic name | Other systemic treatments for PsO |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- A Study to Assess Deucravacitinib Safety in Pregnancy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other systemic treatments for PsO CI brief — competitive landscape report
- Other systemic treatments for PsO updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI